Topline results were announced from a phase 3 trial evaluating icotrokinra in patients with moderate to severe plaque psoriasis (PsO).

Icotrokinra is an investigational oral peptide that blocks interleukin (IL)-23 receptor, which plays a significant role in ...

The study was conducted among patients with plaque psoriasis affecting special areas such as the scalp, genitals and/or hands ...

Discover why analysts are bullish on Arcutis Biotherapeutics after strong Q3 results, despite recent market fluctuations in ...

MALVERN, Pa., Nov. 15, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI ) announced today that it has entered into a definitive agreement with MC2 Therapeutics ("MC2") to commercialize Wynzora® Cream ...

Endo, Inc. (OTCQX: NDOI) announced today that it has entered into a definitive agreement with MC2 Therapeutics ("MC2") to commercialize Wynzora® Cream ...

Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.

The following medications are indicated for plaque psoriasis, unless otherwise specified ... gently rub in completely. Apply to scalp when hair is dry. Wynzora 0.005% + 0.064% crm Adults: Apply ...

It’s FDA approved to treat moderate to severe plaque psoriasis when phototherapy or systemic therapy is appropriate. you’re pregnant or nursing (though biologics can still be prescribed if ...

Researchers conducted a retrospective study to investigate the effectiveness of brodalumab for treating difficult-to-manage body regions in moderate-to-severe plaque psoriasis in clinical practice.

Medically reviewed by Doru Paul, MD To confirm a psoriasis diagnosis, your healthcare provider will check your skin and scalp ...